论文部分内容阅读
目的探讨链式激活的免疫细胞(Capri)治疗恶性积液的效果。方法分别观察试验组、化疗组患者恶性积液治疗的有效性和总生存期,应用流式细胞术和RT-PCR法检测2组患者治疗前后不同时间的T淋巴细胞亚群及CK19m RNA的变化。以健康体检者为对照组。结果试验组积液的控制情况和生活质量明显优于化疗组(χ2=7.810,P<0.05;χ2=5.185,P<0.05)。2组患者治疗前CD3+、CD4+、NK细胞含量明显低于对照组(P<0.05),治疗后试验组明显升高,与化疗组同期相比差异有统计学意义(P<0.05),与对照组相比差异无统计学意义(P>0.05)。2组患者治疗前CD8+含量明显高于对照组(P<0.05)。治疗后明显下降,与治疗前相比差异有统计学意义(P<0.05),与对照组相比差异无统计学意义(P>0.05),试验组与化疗组同期相比差异无统计学意义(P>0.05)。2组治疗前CK19m RNA基因表达均显著增强,与对照组相比差异有统计学意义(P<0.05)。治疗后试验组表达显著降低,与治疗前相比差异有统计学意义(P<0.05),与化疗组同期相比差异均有统计学意义(P<0.05)。结论恶性积液患者可以应用Capri细胞治疗,Capri细胞通过改善患者的免疫功能,增加患者NK细胞的数量,提高患者抗肿瘤的能力,有利于恶性积液患者的治疗及预后。
Objective To investigate the effect of chain activated immune cells (Capri) in the treatment of malignant effusion. Methods The efficacy and overall survival of patients with malignant effusion in experimental group and chemotherapy group were observed. The changes of T lymphocyte subsets and CK19mRNA at different time points before and after treatment were detected by flow cytometry and RT-PCR . Health examination for the control group. Results The control group and quality of life in the experimental group were significantly better than those in the chemotherapy group (χ2 = 7.810, P <0.05; χ2 = 5.185, P <0.05). The levels of CD3 +, CD4 + and NK cells in the two groups before treatment were significantly lower than those in the control group (P <0.05). The levels of CD3 +, CD4 + and NK cells in the two groups were significantly higher than those in the control group (P <0.05) There was no significant difference between the two groups (P> 0.05). The levels of CD8 + in the two groups before treatment were significantly higher than those in the control group (P <0.05). Compared with the control group, there was no significant difference between the two groups (P> 0.05), the difference between the experimental group and the chemotherapy group was not statistically significant (P> 0.05). The mRNA expression of CK19m in both groups before treatment was significantly increased compared with the control group (P <0.05). After treatment, the expression of the test group was significantly lower than that before treatment, the difference was statistically significant (P <0.05), compared with the chemotherapy group compared with the same period (P <0.05). Conclusions Capri cells can be used in patients with malignant effusion. Capri cells can improve the immune function of patients and increase the number of NK cells in patients with malignant effusion, and improve the ability of anti-tumor in patients with malignant effusion.